Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Quantification and structure elucidation of in vivo bevacizumab modification in rabbit vitreous humor after intravitreal injection.

Chu KO, Liu DT, Chan KP, Yang YP, Yam GH, Rogers MS, Pang CP.

Mol Pharm. 2012 Dec 3;9(12):3422-33. doi: 10.1021/mp3005403. Epub 2012 Nov 6.

PMID:
23094698
2.

Pharmacokinetics of intravitreal bevacizumab (Avastin).

Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ.

Ophthalmology. 2007 May;114(5):855-9.

PMID:
17467524
3.

Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.

Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X; Tübingen Bevacizumab Study Group., Grisanti S.

Ophthalmology. 2008 Oct;115(10):1750-5, 1755.e1. doi: 10.1016/j.ophtha.2008.04.023. Epub 2008 Aug 16.

PMID:
18708261
4.

Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.

Matsumoto M, Suzuma K, Maki T, Kinoshita H, Tsuiki E, Fujikawa A, Kitaoka T.

Am J Ophthalmol. 2012 May;153(5):896-902.e1. doi: 10.1016/j.ajo.2011.10.006. Epub 2012 Jan 20.

PMID:
22265145
5.

Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.

Moisseiev E, Waisbourd M, Ben-Artsi E, Levinger E, Barak A, Daniels T, Csaky K, Loewenstein A, Barequet IS.

Graefes Arch Clin Exp Ophthalmol. 2014 Feb;252(2):331-7. doi: 10.1007/s00417-013-2495-0. Epub 2013 Oct 31.

6.

Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.

Abrishami M, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B.

Retina. 2009 May;29(5):699-703. doi: 10.1097/IAE.0b013e3181a2f42a. Erratum in: Retina. 2011 Jan; 31(1):208. Zarei Ganavati, Siamak [corrected to Zarei-Ghanavati, Siamak]..

PMID:
19430280
7.

Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.

Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, Hashiguchi T, Maruyama I, Sakamoto T.

Ophthalmology. 2009 May;116(5):921-6. doi: 10.1016/j.ophtha.2008.12.024.

PMID:
19410951
8.

Pharmacokinetics of intravitreal ranibizumab (Lucentis).

Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ.

Ophthalmology. 2007 Dec;114(12):2179-82.

PMID:
18054637
9.

Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.

Ma Y, Zhang Y, Zhao T, Jiang YR.

Am J Ophthalmol. 2012 Feb;153(2):307-313.e2. doi: 10.1016/j.ajo.2011.08.006. Epub 2011 Oct 7.

PMID:
21982107
10.

Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.

Ahn J, Kim H, Woo SJ, Park JH, Park S, Hwang DJ, Park KH.

J Ocul Pharmacol Ther. 2013 Sep;29(7):612-8. doi: 10.1089/jop.2013.0009. Epub 2013 Jun 4.

11.

Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.

Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M.

Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1606-8. doi: 10.1167/iovs.09-4140. Epub 2009 Oct 29.

PMID:
19875666
12.

Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.

Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K.

J Ocul Pharmacol Ther. 2011 Aug;27(4):379-83. doi: 10.1089/jop.2010.0194.

PMID:
21810018
13.

Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.

Roh MI, Kim HS, Song JH, Lim JB, Kwon OW.

Ophthalmology. 2009 Jan;116(1):80-6. doi: 10.1016/j.ophtha.2008.09.036.

PMID:
19118699
14.

Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab.

Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, Matsumura M.

Jpn J Ophthalmol. 2009 May;53(3):243-8. doi: 10.1007/s10384-008-0645-4. Epub 2009 May 31.

PMID:
19484443
15.

Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab.

Sawada O, Kawamura H, Kakinoki M, Ohji M.

Graefes Arch Clin Exp Ophthalmol. 2008 Oct;246(10):1379-81. doi: 10.1007/s00417-008-0874-8. Epub 2008 Jun 26.

PMID:
18581130
16.

Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.

Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T.

Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4807-13. doi: 10.1167/iovs.08-3148. Epub 2009 Mar 25.

PMID:
19324856
17.

Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.

Nonobe NI, Kachi S, Kondo M, Takai Y, Takemoto K, Nakayama A, Hayakawa M, Terasaki H.

Retina. 2009 May;29(5):579-85. doi: 10.1097/IAE.0b013e3181a3b848.

PMID:
19430279
18.

Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans.

Meyer CH, Krohne TU, Holz FG.

Retina. 2011 Oct;31(9):1877-84. doi: 10.1097/IAE.0b013e318217373c.

PMID:
21738089
19.

Predicted biologic activity of intravitreal bevacizumab.

Stewart MW.

Retina. 2007 Nov-Dec;27(9):1196-200.

PMID:
18046224
20.

Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.

Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M.

Invest Ophthalmol Vis Sci. 2012 Aug 24;53(9):5877-80. doi: 10.1167/iovs.12-10164.

PMID:
22836776

Supplemental Content

Support Center